Contact
searchSearch
HMP Global
Login

Psychedelics Topic Center

Cape Cod Symposium Speakers
Overcoming Perception Barriers and Promoting Safe Access to Psychedelics
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Cape Cod Symposium Speakers
Q&As
Exploring the Therapeutic Potential of Psychedelic Treatments in Psychiatry
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network

News Articles

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
News
Microdosing Associated With Increased Mindfulness, Lower Neuroticism in ADHD Patients
11/28/2023
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers...
11/28/2023
Psych Congress Network
News
Compass Pathways Initiates Phase 3 Study of Psilocybin for Treatment-Resistant Depression
11/27/2023
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently...
11/27/2023
Psych Congress Network
Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News
Prenatal Glucocorticoid Exposure Linked With Increased Mental Disorder Risk
01/17/2025
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to...
01/17/2025
Psych Congress Network
A child sleeps in bed on her stomach with her mouth hanging open
News
Loudness of Snoring May Indicate Greater Hyperactivity in Children and Adolescents
01/16/2025
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless...
01/16/2025
Psych Congress Network
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
News
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
01/14/2025
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression...
01/14/2025
Psych Congress Network
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
News
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
01/14/2025
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses...
01/14/2025
Psych Congress Network
News
Meta-Analysis Finds Little Support for Neurofeedback for ADHD
01/13/2025
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show...
01/13/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
News
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
01/08/2025
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with...
01/08/2025
Psych Congress Network
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
News
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
01/08/2025
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate...
01/08/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network

Blogs

Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
Perspectives
Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
04/12/2021
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in...
04/12/2021
Addiction Professional
Blog
Psychedelics in Group Therapy for HIV Survivors Shows Promising Results
10/02/2020
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the...
10/02/2020
Psych Congress Network
Blog
Psych Congress to Bring Psychedelic-Assisted Therapies Into Focus
09/03/2020
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted...
09/03/2020
Psych Congress Network
Blog
Psychedelics and Wellness: What’s the Connection?
12/17/2019
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra...
12/17/2019
Psych Congress Network
Blog
The Psychedelic Aspect of Esketamine is an Opportunity, Not a Side Effect
05/23/2019
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the...
05/23/2019
Psych Congress Network
Blog
A Turning Point for Psychedelics?
06/06/2018
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of...
06/06/2018
Psych Congress Network
Blog
Depression as Disconnection: New Lessons From Psychedelic Psychotherapy Studies
11/02/2017
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies...
11/02/2017
Psych Congress Network
Blog
Psilocybin Studies: A New Ray of Hope for Psychiatry?
12/01/2016
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the...
12/01/2016
Psych Congress Network
Blog
Psychedelics: What to Tell Patients Today
08/25/2015
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are...
08/25/2015
Psych Congress Network
Blog
How Psychedelics May Be Used to Accelerate Psychotherapy
08/19/2015
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment...
08/19/2015
Psych Congress Network
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Rakesh Amin, MD.
Blog
Treating Schizophrenia: The Importance of Early Identification and Intervention
06/13/2023
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the...
06/13/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Ed Jones, PhD
Blog
How Our Clinicians Can Help Fix the US Health Care System
07/28/2022
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the...
07/28/2022
Psych Congress Network
Ed Jones, PhD
Perspective
The Universal Behavior Model: A Comprehensive Approach to Integrated Care
07/21/2022
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this...
07/21/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
Who will use it? How to Get Digital Mental Health Apps Into the Hands of Patients
04/27/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan...
04/27/2022
Psychiatry & Behavioral Health
Chan_Khan_Digital Mental Health
Blog
How to Navigate Quality Issues With Mental Health Apps
04/21/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan...
04/21/2022
Psychiatry & Behavioral Health
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Blog
How New NPs Can Find Mentors
03/04/2022
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains...
03/04/2022
Psych Congress Network
Julie Bailey
Blog
How to Be a Safe Space for Someone
02/08/2022
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey,...
02/08/2022
Psych Congress Network
major depressive disorder
Blog
The Best and Worst Changes Brought On By the Pandemic
01/31/2022
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy...
01/31/2022
Psych Congress Network

Interactive Features

Quiz
Quiz: Psilocybin Named Breakthrough Therapy for Which Condition?
12/10/2019
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug...
12/10/2019
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Which U.S. region saw the most fentanyl pill seizures in 2023?
Quiz
Which US region saw the most fentanyl pill seizures in 2023?
01/15/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
01/15/2025
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Expert Insights Quiz
Resources for Telehealth Rules and Regulations
01/06/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/06/2025
Psych Congress Network
How long does worry need to be present in order to diagnose GAD?
Quiz
How long does worry need to be present in order to diagnose GAD?
01/03/2025
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
01/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Antidepressant Discontinuation Symptoms
12/23/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/23/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Prodromal Symptoms in Schizophrenia
12/18/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/18/2024
Psych Congress Network
Are men or women more affected by depressive episodes?
Quiz
Are men or women more affected by depressive episodes?
12/17/2024
Pop quiz!
Pop quiz!
Pop quiz!
12/17/2024
Psych Congress Network
After how many months is 'problematic' opioid use diagnosed as OUD?
Quiz
After how many months is 'problematic' opioid use diagnosed as OUD?
12/16/2024
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
12/16/2024
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
12/11/2024
Psych Congress Network

Posters

Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
TBD
11/26/2024
Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
How do Patients with Depression and their Providers talk about Anhedonia? An Ethnographic Analysis of Healthcare Provider Conversations with Patients in the Clinical Setting.
Background Anhedonia, a core symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited data exist on how anhedonia is dis...
11/26/2024
Lumateperone in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: Efficacy Across Symptoms
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or II disorder. This prospectively defined analysis of...
11/26/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use